Desvenlafaxine for the Acute Treatment of Depression: A Systematic Review and Meta-analysis

Abstract

Introduction: Desvenlafaxine, the active metabolite of venlafaxine, was approved in 2008 by the FDA for the treatment of depression. The aim of the present review is to provide an overview of the existing trials with desvenlafaxine and assess its overall efficacy and tolerability.

Methods: We searched in PubMed, EMBASE and the Cochrane Library for eligible studies (double-blind randomized control trials). A random effects model was used for the estimation of effect sizes.

Results: 17 trials were found in total. In the placebo-controlled trials the overall risk ratio for response was 1.24 (1.16–1.32, p<0.001), for remission 1.29 (1.16–1.43, p<0.001), for dropouts 1.16 (0.99–1.35, p=0.066) and for dropouts due to adverse events 1.98 (1.45–2.69, p<0.001). There were no differences between the various doses that were used (i. e., 50 mg, 100 mg, 200 mg, 400 mg). The mean risk ratio for response in the head-to-head trials was 0.90 (0.82–0.98, p=0.014) and for remission 0.82 (0.71–0.95, p=0.009).

Discussion: The risk ratios for response and remission were moderate. We further provide some evidence that desvenlafaxine might not be as efficacious as other antidepressants.

Key words

depression - desvenlafaxine - SNRI - review - meta-analysis

• References

• 1 Cipriani A, Furukawa TA, Salanti G et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 2009; 373: 746-758
• 2 Deecher DC, Beyer CE, Johnston G et al. Desvenlafaxine succinate: A new serotonin and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther 2006; 318: 657-665
• 3 Leucht S, Cipriani A, Spineli L et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013; 382: 951-962
• 4 Thase ME, Kornstein SG, Germain JM et al. An integrated analysis of the efficacy of desvenlafaxine compared with placebo in patients with major depressive disorder. CNS Spectr 2009; 14: 144-154
• 5 Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions. In The Cochrane Library, Volume Issue 4. Chichester, UK: John Wiley & Sons, Ltd;; 2006
• 6 Friedrich JO, Adhikari NKJ, Beyene J. Inclusion of zero total event trials in meta-analyses maintains analytic consistency and incorporates all available data. BMC Med Res Methodol 2007; 7: 5
• 7 Furukawa TA, Cipriani A, Barbui C et al. Imputing response rates from means and standard deviations in meta-analyses. Int Clin Psychopharmacol 2005; 20: 49-52
• 8 Borenstein M, Hedges RV, Higgins JPT et al. Introduction to Meta-Analysis. West Sussex: Wiley; Edition 2009
• 9 Neyeloff JL, Fuchs SC, Moreira LB. Meta-analyses and forest plots using a Microsoft Excel spreadsheet: step-by-step guide focusing on descriptive data analysis. BMC Res Notes 2012; 5: 52 http://www.biomedcentral.com/1756-0500/5/52
• 10 Egger M, Davey Smith G, Schneider M et al. Minder C. Bias in meta-analysis detected by a simple graphical test. BMJ 1997; 315: 629-634
• 11 DeMartinis NA, Yeung PP, Entsuah R et al. A double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder. J Clin Psychiatry 2007; 68: 677-688
• 12 Liebowitz MR, Yeung PP, Entsuah R. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in adult outpatients with major depressive disorder. J Clin Psychiatry 2007; 68: 1663-1672
• 13 Septien-Velez L, Pitrosky B, Padmanabhan SK et al. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder. Int Clin Psychopharmacol 2007; 22: 338-347
• 14 Boyer P, Montgomery S, Lepola U et al. Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial. Int Clin Psychopharmacol 2008; 23: 243-253
• 15 Lieberman DZ, Montgomery SA, Tourian KA et al. A pooled analysis of two placebo-controlled trials of desvenlafaxine in major depressive disorder. Int Clin Psychopharmacol 2008; 23: 188-197
• 16 Liebowitz MR, Manley AL, Padmanabhan SK et al. Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder. Curr Med Res Opin 2008; 24: 1877-1890
• 17 Feiger AD, Tourian KA, Rosas GR et al. A placebo-controlled study evaluating the efficacy and safety of flexible-dose desvenlafaxine treatment in outpatients with major depressive disorder. CNS Spectr 2009; 14: 41-50
• 18 Tourian KA, Padmanabhan SK, Groark J et al. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies. Clin Ther 2009; 31: 1405-1423
• 19 Iwata N, Tourian KA, Hwang E et al. Efficacy and safety of desvenlafaxine 25 and 50mg/day in a randomized, placebo-controlled study of depressed outpatients. J Psychiatr Pract 2013; 19: 5-14
• 20 Liebowitz MR, Tourian KA, Hwang E et al. Study 3362 Investigators. A double-blind, randomized, placebo-controlled study assessing the efficacy and tolerability of desvenlafaxine 10 and 50 mg/day in adult outpatients with major depressive disorder. BMC Psychiatry 2013; 13: 94
• 21 Clayton AH, Tourian KA, Focht K et al. Desvenlafaxine 50 and 100 mg/d versus placebo for the treatment of major depressive disorder: a phase 4, randomized controlled trial. J Clin Psychiatry 2014; Oct 28. [Epub ahead of print]
• 22 Kornstein SG, Jiang Q, Reddy S et al. Short-term efficacy and safety of desvenlafaxine in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder. J Clin Psychiatry 2010; 71: 1088-1096
• 23 Clayton AH, Kornstein SG, Dunlop BW et al. Efficacy and safety of desvenlafaxine 50 mg/d in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder. J Clin Psychiatry 2013; 74: 1010-1017
• 24 Dunlop BW, Reddy S, Yang L et al. Symptomatic and functional improvement in employed depressed patients: a double-blind clinical trial of desvenlafaxine versus placebo. J Clin Psychopharmacol 2011; 31: 569-576
• 25 Soares CN, Thase ME, Clayton A et al. Desvenlafaxine and escitalopram for the treatment of postmenopausal women with major depressive disorder. Menopause 2010; 17: 700-711
• 26 Schueler YB, Koesters M, Wieseler B et al. A systematic review of duloxetine and venlafaxine in major depression, including unpublished data. Acta Psychiatr Scand 2011; 123: 247-265
• 27 Papakostas GI, Fava M. Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD. Eur Neuropsychopharmacol 2009; 19: 34-40
• 28 Bridge JA, Birmaher B, Iyengar S et al. Placebo response in randomized controlled trials of antidepressants for pediatric major depressive disorder. Am J Psychiatry 2009; 166: 42-49
• 29 Coleman KA, Xavier VY, Palmer TL et al. An indirect comparison of the efficacy and safety of desvenlafaxine and venlafaxine using placebo as the common comparator. CNS Spectr 2012; 17: 131-141
• 30 ACADIA Pharmaceuticals. ACADIA Pharmaceuticals Announces Results from ACP-104 Phase IIb Schizophrenia Trial. (Jun 16); 2008 Internet http://news.acadia-pharm.com/phoenix.zhtml?c=125180&p=irol-newsArticle&ID=1166151
• 31 DrugBank 4.0: shedding new light on drug metabolism . Law V, Knox C, Djoumbou Y et al. Nucleic Acids Res 2014; 42: D1091-D1097 PubMed ID: 24203711. Available from http://www.drugbank.ca/drugs/DB06731#references